However, treatment with AMPK inhibitor compound C remarkably reverses the above-mentioned effects, suggesting that FGF19 has a protective role on the heart by averting oxidative stress-related diabetic cardiomyopathy through activation of the AMPK/Nrf2/HO-1 pathway [14]. The gene discussed is PRKAA1; the disease is diabetic cardiomyopathy.